Clinicopathologic and cytogentic features of CD34 (My 10)-positive acute nonlymphocytic leukemia

M. J. Borowitz, J. P. Gockerman, J. O. Moore, C. I. Civin, S. O. Page, J. Robertson, S. H. Bigner

Research output: Contribution to journalArticlepeer-review

Abstract

The authors performed membrane antigen phenotyping on 75 patients with acute nonlymphocytic leukemia with a panel of myeloid-associated monoclonal antibodies. The 34 patients (45%) with CD34-positive leukemia were not significantly different from the 41 with CD34-negative leukemia with respect to age, hemoglobin, white blood cell count, or platelet count at presentation, but their blasts were more likely to lack the CD15 or CD33 antigens and to have FAB M1 or M2 morphologic characteristics. CD34-positive leukemia was more likely to arise after chemotherapy. Patients with CD34-positive leukemia were less likely to enter a complete remission even when analysis was limited to those patients receiving a high-dose induction-type chemotherapy regimen. Giemsa-banding karyotyping studies were obtained in 55 of the cases. In 30 of these cases (56%) clonal karyotypic abnormalities were demonstrated. Although the karyotypic abnormalities and phenotypes were varied, there was a high degree of association between the karyotypic abnormalities monosomy 7/del (7q) and the CD-34-positive phenotype; this antigen was expressed on blasts from eight of the nine patients displaying this abnormality. Monoclonal antibody phenotyping of myeloid leukemia with reagents such as anti-CD34 may help to define biologically interesting subsets of ANLL with distinct clinico-pathologic expression.

Original languageEnglish (US)
Pages (from-to)265-270
Number of pages6
JournalAmerican journal of clinical pathology
Volume91
Issue number3
DOIs
StatePublished - Jan 1 1989
Externally publishedYes

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint

Dive into the research topics of 'Clinicopathologic and cytogentic features of CD34 (My 10)-positive acute nonlymphocytic leukemia'. Together they form a unique fingerprint.

Cite this